Gut Microbiome May Predict Treatment Side Effects & New T-cell Therapies Aimed at EBV

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, readsa news article on how differences in the gut microbiome have been linked to an altered risk of developing low immune cell counts following treatment with Tecfidera.He also reads a second article reporting that Tevogen Bio has announced plans to develop T-cell therapies that target the Epstein-Barr virus.=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:https://multiplesclerosisnewstoday.com/=====================================To join in on conversations regarding multiple sclerosis, please visit:https://multiplesclerosisnewstoday.com/forums/